Weak Trigger
now
Formally announces successful completion of dosing for Cohort 2 in the Phase 1/2 clinical trial of 'OCU410', a modifier gene therapy for Stargardt disease.
24h Trigger History
No history available
No trigger updates found for this ticker in the last 24 hours.
| Advertisement |